BioSpace News Archive

Following Multiple Years of Strong Growth, Financing Further Validates 503B Industry Value Proposition, Demonstrates Strength of QuVa Pharma and Attractiveness of Ongoing Business Growth Initiatives

Three-target, multi-year collaboration includes the development of bispecific antibodies to treat sight-threatening complication of type 1 and 2 diabetes

AIROS® Medical, Inc., a medical technology manufacturer specializing in compression therapy products that treat cancer-related lymphedema and venous complications, announced its partnership with Lisa’s Army, a 501 non-profit organization that provides comfort and encouragement to individuals undergoing cancer treatment.

RxMx Corp., in partnership with Sanofi, a global biopharmaceutical company, has won the “Best Healthcare Big Data Solution” award from the MedTech Breakthrough Awards for a program and series of technology products.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it had received “Notice of Allowance” from the Mexican Patent and Trademark Office (IMPI) in relation to the company’s patent titled: ‘System and method for high throughout screening of cancer cells”

Pfizer Canada, Novatek International, Cognistat and Member of Parliament for Saint-Laurent, Emmanuella Lambropoulos, have joined forces to achieve Hope for Dementia’s mission to end isolation and loneliness in senior care homes.

Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved a single 1000 mg dose option of Injectafer®

The Aplastic Anemia and MDS International Foundation (AAMDSIF) and the National Organization for Rare Disorders (NORD®) today launched the largest-ever study to research Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare bone marrow failure disease

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Record Quarterly Revenue Growth Up 97.4% to $60.5 Million North America Point of Care Lab Consumables Sales Up 23.9%